Showing 2630 results
- https://www.novartis.com/news/media-releases/sandoz-extends-collaboration-agreement-drive-cutting-edge-digital-solutions-global-fight-against-antimicrobial-resistance-amrExtending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening…
- https://www.novartis.com/news/world-sight-day-2020
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.
- https://www.novartis.com/news/media-releases/novartis-announces-anti-pd-1-tislelizumab-accepted-ema-regulatory-review-esophageal-and-lung-cancersEuropean Medicines Agency validated MAAs for tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indicationsSubmissions based on data from Phase III RATIONALE…
- https://www.novartis.com/stories/staying-one-step-ahead-malaria-parasite
Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.
- https://www.novartis.com/news/standing-racial-equity-and-justice-one-novartis
- https://www.novartis.com/stories/cancer-cocktails-abl001-hitting-one-target-twice
- https://www.novartis.com/news/media-releases/novartis-announces-early-clinical-data-unique-krasg12c-inhibitor-american-association-cancer-research-annual-meetingJDQ443, an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor, shows 57% confirmed ORR at recommended dose of 200 mg twice daily in Phase Ib study in patients with…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-5Shareholders approve 25th consecutive dividend increase to CHF 3.10 (+3.3%) per share for 2021; representing a 3.9% yield1 and approximately 57% payout of free cash flowShareholders confirm Dr. Joerg…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-toutes-les-resolutions-proposees-par-le-conseil-dadministration-lors-de-lassemblee-generale-ordinaireLes actionnaires approuvent la 25e augmentation consécutive du dividende qui passe à CHF 3.10 (+3,3%) par action pour 2021; représentant un rendement de 3.9%1 et une distribution du free cash-…
- https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-heissen-der-ordentlichen-generalversammlung-alle-antrage-des-verwaltungsrats-gutDie Aktionäre genehmigen die 25. Dividendenerhöhung in Folge auf CHF 3.10 (+3,3 %) pro Aktie für 2021; dies entspricht einer Rendite von 3.9 %1 und einer Ausschüttung von rund 57 % des freien…
Pagination
- ‹ Previous page
- 1
- …
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- …
- 263
- › Next page